Everything on Healthcare & M&A

Pharmaceutical M&A is shifting from pipeline-driven growth to cost consolidation, reflecting investor skepticism toward patent cliff mitigation strategies.

Impact: Life science portfolios may face valuation compression unless firms demonstrate clear commercialization synergies and regulatory compliance.

— from Global Market Shifts: AI, Pharma M&A, and Consumer Realignment · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Aug 04, 2026